Stem definition | Drug id | CAS RN |
---|---|---|
2144 | 63-91-2 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
None | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Foetal growth restriction | 68.71 | 37.45 | 15 | 396 | 6552 | 46679099 |
Infantile apnoea | 48.61 | 37.45 | 8 | 403 | 768 | 46684883 |
Selective eating disorder | 42.14 | 37.45 | 8 | 403 | 1737 | 46683914 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|
Source | Code | Description |
---|---|---|
CHEBI has role | CHEBI:27027 | trace elements |
CHEBI has role | CHEBI:50733 | nutritional supplement |
CHEBI has role | CHEBI:63332 | alkaline phosphatase inhibitors |
CHEBI has role | CHEBI:75771 | mus musculus metabolite |
CHEBI has role | CHEBI:75772 | baker's yeast metabolite |
CHEBI has role | CHEBI:76924 | plant metabolites |
CHEBI has role | CHEBI:76967 | human xenobiotic metabolites |
CHEBI has role | CHEBI:76971 | e.coli metabolites |
CHEBI has role | CHEBI:84735 | algal metabolites |
CHEBI has role | CHEBI:83056 | daphnia magna metabolites |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Classical phenylketonuria | contraindication | 7573000 | |
Poisoning by digitalis glycoside | contraindication | 12876009 | |
Sarcoidosis | contraindication | 31541009 | DOID:11335 |
End stage renal disease | contraindication | 46177005 | DOID:784 |
Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
Heart disease | contraindication | 56265001 | DOID:114 |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Ventricular fibrillation | contraindication | 71908006 | |
Hypercalciuria | contraindication | 71938000 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Kidney stone | contraindication | 95570007 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.27 | acidic |
pKa2 | 9.25 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Probable G-protein coupled receptor 139 | Unclassified | AGONIST | IC50 | 4.51 | IUPHAR | ||||
Voltage-dependent calcium channel subunit alpha-2/delta-1 | Ion channel | Ki | 6.01 | CHEMBL | |||||
Intestinal alkaline phosphatase | Unclassified | IC50 | 4.10 | CHEMBL | |||||
L-type amino acid transporter 1 | Unclassified | Ki | 4.26 | CHEMBL |
ID | Source |
---|---|
4018673 | VUID |
N0000146984 | NUI |
4018673 | VANDF |
C0031453 | UMLSCUI |
CHEBI:17295 | CHEBI |
PHE | PDB_CHEM_ID |
CHEMBL301523 | ChEMBL_ID |
D010649 | MESH_DESCRIPTOR_UI |
DB00120 | DRUGBANK_ID |
3313 | IUPHAR_LIGAND_ID |
6168 | INN_ID |
47E5O17Y3R | UNII |
6140 | PUBCHEM_CID |
8156 | RXNORM |
NOCODE | MMSL |
003542 | NDDF |
421626005 | SNOMEDCT_US |
63004003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
ProcalAmine | HUMAN PRESCRIPTION DRUG LABEL | 22 | 0264-1915 | INJECTION | 0.17 g | INTRAVENOUS | NDA | 24 sections |
TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 0.48 g | INTRAVENOUS | NDA | 23 sections |
Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-3200 | SOLUTION | 1.04 g | INTRAVENOUS | ANDA | 20 sections |
Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-3205 | SOLUTION | 1.04 g | INTRAVENOUS | ANDA | 20 sections |
Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-4500 | SOLUTION | 1.04 g | INTRAVENOUS | ANDA | 20 sections |
FreAmine III | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0264-9010 | INJECTION, SOLUTION | 0.56 g | INTRAVENOUS | NDA | 24 sections |
FreAmine III | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0264-9011 | INJECTION, SOLUTION | 0.56 g | INTRAVENOUS | NDA | 24 sections |
TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-9341 | SOLUTION | 0.48 g | INTRAVENOUS | NDA | 23 sections |
FreAmine HBC | HUMAN PRESCRIPTION DRUG LABEL | 15 | 0264-9350 | INJECTION, SOLUTION | 0.32 g | INTRAVENOUS | NDA | 24 sections |
TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-9361 | SOLUTION | 0.29 g | INTRAVENOUS | NDA | 23 sections |
HepatAmine | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0264-9371 | INJECTION, SOLUTION | 0.10 g | INTRAVENOUS | NDA | 23 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0180 | INJECTION | 448 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0184 | INJECTION, EMULSION | 448 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0188 | INJECTION | 448 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0194 | INJECTION | 448 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0198 | INJECTION | 336 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0202 | INJECTION | 448 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0206 | INJECTION | 448 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0210 | INJECTION | 448 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0214 | INJECTION | 448 mg | INTRAVENOUS | NDA | 20 sections |
ProSol | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0338-0499 | INJECTION, SOLUTION | 1 g | INTRAVENOUS | NDA | 21 sections |
Clinisol | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0338-0502 | INJECTION, SOLUTION | 1.04 g | INTRAVENOUS | ANDA | 18 sections |
Travasol | HUMAN PRESCRIPTION DRUG LABEL | 15 | 0338-0644 | INJECTION | 560 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1089 | INJECTION | 238 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1091 | INJECTION | 238 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1099 | INJECTION | 280 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1101 | INJECTION | 280 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1113 | INJECTION | 238 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1115 | INJECTION | 238 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1123 | INJECTION | 280 mg | INTRAVENOUS | NDA | 20 sections |